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Abstract
Background: Case-control studies of mass screening for lung cancer (LC) by chest x-rays (CXR) performed in the
1990s in scarcely defined Japanese target populations indicated significant mortality reductions, but these results
are yet to be confirmed in western countries. To ascertain whether CXR screening decreases LC mortality at
community level, we studied a clearly defined population-based cohort of smokers invited to screening. We
present here the LC detection results and the 10-year survival rates.
Methods: The cohort of all smokers of > 10 pack-years resident in 50 communities of Varese, screening-eligible (n
= 5,815), in July 1997 was invited to nonrandomized CXR screening. Self-selected participants (21% of cohort)
underwent screening in addition to usual care; nonparticipants received usual care. The cohort was followed-up
until December 2010. Kaplan-Meier LC-specific survival was estimated in participants, in nonparticipants, in the
whole cohort, and in an uninvited, unscreened population (control group).
Results: Over the initial 9.5 years of study, 67 LCs were diagnosed in screening participants (51% were screen-
detected) and 178 in nonparticipants. The rates of stage I LC, resectability and 5-year survival were nearly twice as
high in participants (32% stage I; 48% resected; 30.5% 5-year survival) as in nonparticipants (17% stage I; 27%
resected; 13.5% 5-year survival). There were no bronchioloalveolar carcinomas among screen-detected cancers, and
median volume doubling time of incidence screen-detected LCs was 80 days (range, 44-318), suggesting that
screening overdiagnosis was minimal. The 10-year LC-specific survival was greater in screening participants than in
nonparticipants (log-rank, p = 0.005), and greater in the whole cohort invited to screening than in the control
group (log-rank, p = 0.001). This favourable long-term effect was independently related to CXR screening exposure.
Conclusion: In the setting of CXR screening offered to a population-based cohort of smokers, screening
participants who were diagnosed with LC had more frequently early-stage resectable disease and significantly
enhanced long-term LC survival. These results translated into enhanced 10-year LC survival, independently related
to CXR screening exposure, in the entire population-based cohort. Whether increased long-term LC-specific survival
in the cohort corresponds to mortality reduction remains to be evaluated.
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Background
The historical observational studies of chest x-ray (CXR)
screening for lung cancer (LC) showed improved LC-spe-
cific survival but no reduction of LC-specific mortality
[1-6]. Four case-control studies performed in the 1990s
in Japan on a population level however suggested CXR
screening effectiveness, as indicated by LC mortality
reductions of about 40% [7,8]. The results of these case-
control studies were obtained in scarcely defined target
populations, were likely biased by self-selection and are
yet to be confirmed in western countries. Randomized
trials of LC screening by chest radiography performed in
the 1970s [9,10] failed to answer the question of efficacy
of radiographic screening, likely due to methodological
flaws [11]; however, the possibility was recognized that a
small but important benefit from annual CXR could have
been missed [12-14]. The lung component of the Pros-
tate, Lung, Colon and Ovarian (PLCO) cancer screening
randomized trial was carried out to definitively assess the
efficacy of CXR screening [15]. The recently published
PLCO results showed that four annual chest radiographs
did not reduce LC-specific mortality in volunteers [16],
but it remains uncertain whether this finding may be
generalized on a population level.
In 1997 we started to study the PREDICA cohort
(hereafter concisely referred to as “cohort”), a clearly
defined population-based cohort of 5,815 heavy or long-
term smokers of the Province of Varese, Italy, to ascer-
tain whether CXR screening at community level
decreases LC mortality [17]. The cohort was invited to
an annual CXR screening program and was followed-up
for 13.5 years. Our aim is to evaluate here the LC detec-
tion results and the long-term LC survival in screening
participants as well as in nonparticipants of this popula-
tion-based cohort. We also examine LC survival by
intent-to-screen, in the entire cohort invited to screen-
ing. This analysis is preliminary to the evaluation of
CXR screening effectiveness on a population level by the
LC mortality indicator, to be reported at a later date.
Methods
Summary of study design
The design is a nonrandomized LC screening study of a
defined population-based cohort of asymptomatic smo-
kers. In July 1997 the cohort was offered annual CXR
screening for 4 years and was observed for 13.5 years.
The individuals who self-selected to participate under-
went screening in addition to the Italian National Health
System (NHS) usual care; nonparticipants received usual
care only. At the end of the active screening period, we
evaluated the rate of positive CXR screens, the LC yield,
and the invasive procedures performed to follow-up
radiographic abnormalities. Moreover, the clinico-patho-
logical features of all LCs diagnosed in the initial 9.5
years of study were examined in participants and in
nonparticipants. The whole cohort was subsequently fol-
lowed-up until study cut off, December 31, 2010. The
main outcome was LC specific survival from time of
cancer diagnosis in participants, in nonparticipants, and
in the whole cohort relative to a control group. Second-
ary outcomes were the LC detection results.
Cohort (n = 5,815)
Recruitment modalities and characteristics of the cohort
have been described [17]. Briefly, recruitment was
effected by 50 general practitioners (GP) physicians col-
laborating on the study, who served altogether a popula-
tion of about 60,000 adults in communities widely
spread over the Varese Province. In early 1997 the GPs
compiled a preliminary recruitment list, encrypted to
comply with privacy regulations, pooling all smokers
resident in the communities of their practice who met
the screening criteria: cigarette smoker of > 10 pack-
years (current smoker or ex-smoker for < 10 years), resi-
dent in the Varese Province, both genders, aged 45-75
years, fit for possible thoracotomy, without symptoms
(bloody or worsening cough, hoarseness, unexplained
weight loss) and without diagnosed or suspected LC. No
other exclusion criteria were used. The 50 GPs served
nearly 100% of residents in their respective commu-
nities, in the NHS. They recruited all cigarette smokers
in their public medical practices who were screening-eli-
gible, based on self-reported smoking history abstracted
from medical records. Completeness of the recruitment
list was ascertained by the quality assurance team of the
project (AI, MP, VD, and APa). Finally, the cohort con-
sisted of 5,815 screening-eligible smokers. Their mean
age was 56.6 years (8.3 SD), males were 73.7%, current
smokers were 76.3% and the median pack-years smoked
was 32.8 (interquartile range (IQR), 22.8-46.0) [17]. Tar-
geted subjects were told nothing of the study until the
screening recruitment list was complete. On May 1997 a
letter informing all cohort subjects about risks and pos-
sible benefits of CXR screening (significantly increased
resectability and survivorship of screen-detected lung
cancer) was sent out. The letter also served as invitation
to participate in LC screening free of charge. Moreover,
the screening project was widely publicized in the local
media. Signed informed consent was obtained from all
individuals who accepted to participate in screening. For
nonparticipants, informed consent was waived and their
names were encrypted, as approved by the Varese Hos-
pital and Health District Ethics Committee.
Screening participants and timeline of study
The study lasted from July 1, 1997 until December 31,
2010. Enrolment of screening participants extended for
4.5 years, until December 31, 2001, although it
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concentrated early in the study (median enrolment, Feb-
ruary 1998). As published in the initial report of the
cohort, 1,244 subjects (21% of the cohort) undertook at
least the baseline CXR screening by December 31, 2001
and were allocated as participants [17]. The other 4,571
subjects were nonparticipants. All cohort individuals
were observed from start of study until December 31,
2010 when the study was cut off, or until date of death,
whichever came first. We examined the LC detection
results and the survival of all LCs diagnosed in the
cohort during the period from July 1, 1997 until Decem-
ber 31, 2006, giving each survivor a potential minimum
follow-up of 48 months.
CXR screening and management of positive screens
The screening protocol consisted of baseline CXR and
annual repeat screen for 4 years. Chest radiographs were
taken as described previously [17] and were interpreted
with single reading by one of three senior thoracic radiol-
ogists, in comparison with previous images if available. A
CXR was defined positive when a nodule, mass or infil-
trate was identified as suspicious for LC, at the radiolo-
gist’s discretion. After undertaking the baseline screen,
participants with negative CXR reading were scheduled
for subsequent annual appointments and received an
annual reminder. Participants with positive CXR screens,
and all subjects in the cohort with nonscreen-detected
abnormalities suspicious for LC, were referred to the
thoracic oncologists of the Varese University Hospital for
diagnostic follow-up. The standard of care in Varese for
the investigation of suspicious abnormalities was used,
initially consisting of repeat imaging by CXR or com-
puted tomography (CT) after 1-month to 6-month inter-
val, depending on the degree of LC suspect. If necessary,
histologic/cytologic diagnosis was obtained by the least
invasive method, chosen among fine-needle aspiration
cytology (FNAC), bronchoscopic biopsy and video-
assisted thoracoscopic (VATS) lung wedge resection.
Regardless of the detection modality, by screening or out-
side screening, the LCs diagnosed in this study were trea-
ted by usual international criteria [18]. Management of
LCs was centralized in the Varese University Hospital,
with the exception of very few patients treated at nearby
private hospitals essentially with the same standard of
care. All individuals with suspect LC who were candidate
for active cancer treatment had histological/cytological
confirmation of diagnosis and the LCs were staged
according to the 6th ed. of TNM Classification of Malig-
nant Tumors [19]. The LC diagnosis was clinico-radiolo-
gic in patients who refused biopsy or treatment and in
those subjects who were candidates for supportive care
only. Except for patients scheduled for induction chemo-
or radiotherapy, LC cases candidate to surgery were
operated within one month from diagnosis. We
prospectively recorded all LCs diagnosed in the cohort
during the initial 9.5 years of study, adopting the Varese
Cancer Registry criteria [17,20], by linkage with the Epi-
demiology Observatory [21], Varese Cancer Registry,
Varese Province hospital records and pathology records.
In screening participants the LCs were classified either as
screen-detected or nonscreen-detected (i.e. diagnosed as
interval cases or outside of screening). We recorded the
size of screen-detected cancers and calculated the volume
doubling time (VDT) of cancers diagnosed at incidence
screening, based on tumor size measurements from
sequential CXRs. To calculate VDT of a lung tumor not
evident retrospectively on the prior radiograph, the
tumor was arbitrarily attributed the dimension of 6 mm
on the prior CXR, corresponding to the estimated visibi-
lity threshold [22]. Follow-up included review of medical
records for collection of data concerning LC histology,
stage at diagnosis and treatment. The LC deaths occurred
in the cohort during the 13.5 year observation period
were searched by linkage with the Varese Mortality Reg-
istry, last accessed on April 27, 2011. Date and cause of
death were obtained from death certificates of the Regis-
try. For subjects who had migrated within the Lombardy
region, survival status were ascertained by linkage with
the Lombardy Health Registry of residents [23]; for sub-
jects not traceable through this registry, investigations
were done among persons’ next-of-kin and via demo-
graphic services. Death certificates were reviewed by the
mortality review committee members (LD, AI, NR, FS,
SP, APo and WM), who were not blinded to the mode of
LC detection. Those deaths definitely attributed to LC we
recorded as LC-specific deaths.
Control LC group
A control group of uninvited and unscreened LC
patients prospectively followed-up was identified, to
be used as comparator for LC cases found in the
cohort. To that effect we accessed the database of all
LC cases (n = 243) diagnosed during the calendar
year 2000 in the 350,000 residents of the Varese dis-
trict area. The year 2000 LC cases were chosen
because the demographic and clinico-pathological
data of all these patients were available and published
[18,24], and their 10-year follow-up was obtained by
linkage with Varese Epidemiology Observatory [21].
Of the 243 LC patients diagnosed in 2000, 156 sub-
jects met the screening criteria as of July 1997 (birth-
year cohort, smoking history, residence in the district
of the cohort, uninvited to screening and unscreened)
and constituted the control LC group of the present
study. The cause of death of the control LC group
subjects was assigned by the mortality review com-
mittee, as described above for deceased subjects of
the cohort.
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Statistical analysis
Continuous variables were reported as mean with stan-
dard deviation (SD), or median with range or interquar-
tile range (IQR, 25th-75th percentiles). Categorical data
were presented as numbers and percentages. The com-
parison between groups was made using Student’s t-test,
or Mann-Whitney U test, for continuous variables. Cate-
gorical data were compared by Chi-square test, or by
Fischer exact test if necessary. LC survival was defined
as the time from LC diagnosis to LC-related death and
was censored at the last follow-up date (December 31,
2010) if no events occurred. In the survival analysis, fol-
low-up time was stopped at 120 months. Survival prob-
ability was estimated according to the Kaplan-Meier
method, and log-rank test was used for comparison of
survival between groups. Multivariate analysis was per-
formed by the Cox regression model to evaluate the
relative role of different screening exposures in predict-
ing prognosis. Gender, age, pack-years and LC histology
were considered as potential confounders. All tests were
two-sided. P values < 0.05 were considered statistically
significant. Analysis was performed at the Department
of Public Health and Community Medicine, University
of Verona (APo, WM), using Stata software 11.0 (Stata
Corporation, College Station, Texas, USA).
This study was approved by the Varese Hospital and
Health District Ethics Committee.
Results
After baseline screening, the absolute number and the
proportion of participants in each annual round (T)
were: T1, 1,046 (84.1%); T2, 876 (70.4%); T3, 735
(59.1%); T4, 566 (45.5%). In addition, we traced 429 sub-
jects (34.5% of participants) who completed the planned
screening rounds and after discussion with their physi-
cian continued annual CXR screening. There were 1,114
of these additional annual CXR screens performed until
December 31, 2006, and their outcomes were included
in the analysis of results. Some of the participants coop-
erated incompletely, slightly extending the interval
between screens, or not attending scheduled exams.
Overall, 5,581 screening tests were performed (baseline,
n = 1,244; incidence, n = 4,337). The median number of
CXR screenings done by each participant, including the
baseline and the above mentioned additional tests, was 4
(IQR, 2-7).
Evaluation of positive screens (Table 1)
Of the total 5,581 CXR exams performed, 224 (4.01%)
were interpreted as positive. The rate of positive tests
was 4.34% (54 of 1,244 participants) at baseline and
3.92% (170 of 4,337) at annual screens. Of the total 224
positive screens, 190 (84.8%) were false-positive (3.4% of
the 5,581 tests performed in total). One FNAC, 8 VATS
lung wedge resections and no lobectomies were done to
biopsy 8 lesions that were benign (3 hamartomas, 3
fibroses, 1 infarct, 1 pneumonia). Overall the rate of
invasive diagnoses for benign lesions was 1.6/1,000 CXR
exams.
There were 34 true positive CXRs (0.61%); in 24 cases
(72%) the LCs were peripherally located. The LC detec-
tion rate was 1.04% (13 of 1,244) at baseline screening,
and 0.48% (21 of 4,337) at annual screens.
Lung cancers detected in the cohort and in the control
group
Overall, 245 LC patients were diagnosed in the cohort.
Table 2 shows their demographics, pack-years, propor-
tion of asymptomatic diagnoses, LC histology and stage
distribution, compared with the corresponding data of
control group LC patients. Characteristics of LC patients
were similar in the cohort and in the control group,
except for a slight preponderance of adenocarcinomas
in the cohort (33% vs. 27%). The proportion of asympto-
matic diagnoses was higher in the cohort (27.3% vs.
18.6%), as expected. The characteristics of participants
and nonparticipants who were diagnosed with LC are
shown in Table 3 and Table 4. There were 67 LCs
found in the 1,244 screening participants and 178 LCs
in the 4,571 nonparticipants. Of the LCs diagnosed in
participants, 34 (51%) were screen-detected and 33
(49%) were nonscreen-detected (interval cases and cases
diagnosed outside screening). In the 34 screen-detected
LCs, mean tumor size was 3.1 ± 1.6 cm; in the 18
screen-detected LCs in stage I, the mean size was 2.9 ±
1.1 cm. The VDT was calculated for all 21 non-baseline
screen-detected cases. For 16 of these cases the lung
tumors were not evident retrospectively on the prior
Table 1 Positive screens, invasive follow-up procedures and screen-detected lung cancers
Baseline Screening
(n = 1,244)
Annual Incidence Screening (n = 4,337) All Screens (n = 5,581)
Positive screens, n (%) 54 (4.34) 170 (3.92) 224 (4.01)
Any invasive procedure, n (%) 15 (1.21) 27 (0.62) 42 (0.75)
Invasive procedure for benign lesion, n (%) 3 (0.24) 6 (0.14) 9 (0.16)
Screen-detected cancers, n (%) 13* (1.04) 21 (0.48) 34* (0.61)
*1 patient: positive sputum cytology
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Table 2 Characteristics of lung cancer (LC) patients in the cohort and in the control group
Patients with LC
Cohort
(n = 245)
Control Group
(n = 156)
P
Age, median (IQR) 68 (60-73) 68 (62-73) 0.930
Male/female (ratio) 221/24 (9.2) 144/12 (12.0) 0.472
Pack-years, median (IQR) 49 (36-66)a 45 (30-67)b 0.598
Asymptomatic LC diagnosis*, n (%) 67 (27.3%) 27 (18.6%)c 0.051
Histologically confirmed LC, n (%) 211 (86%) 131(84%)
Adenocarcinoma, n (%) 69 (33%) 36 (27%)
Squamous cell carcinoma, n (%) 82 (39%) 64 (49%) 0.411
Other NSCLC, n (%) 31 (15%) 14 (11%)
SCLC, n (%) 29 (14%) 17 (13%)
Stage of LC at diagnosisd, e
I, n (%) 49 (21%) 23 (15%)
II, n (%) 13 (6%) 9 (6%)
IIIA, n (%) 30 (13%) 20 (13%) 0.433
IIIB-IV and extensive SCLC, n (%) 136 (60%) 102 (66%)
Follow-up months, median (range)f 101 (49-161) 123 (119-131) 0.232
LC: lung cancer; IQR: interquartile range; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer
*In nonparticipants of the cohort and in the control group the asymptomatic LCs diagnosed were all incidentally found, as documented by patient file review
aNot available in 28 patients
bNot available in 41 patients
cNot available in 11 patients
dNot available in 17 patients of Cohort
eNot available in 2 patients of Control Group
fCalculated in survivors at end of study
Table 3 Characteristics of screening participants and of nonparticipants who were diagnosed with lung cancer (LC)
Participants with LC (n = 67) Nonparticipants with LC (n = 178) P
Age, median (IQR) 66 (60-72) 69 (61-74) 0.196
Male/female (ratio) 60/7 (8.6) 161/17 (9.5) 0.834
Pack-years, median (IQR) 48 (36-68)a 49 (36-66)b 0.768
Histologically confirmed LC, n (%) 63 (94%) 148 (83%) 0.047
Adenocarcinoma, n (%) 18 (29%) 51 (34%)
Squamous cell carcinoma, n (%) 27 (43%) 54 (37%) 0.573
Other NSCLC, n (%) 7 (11%) 25 (17%)
SCLC, n (%) 11 (17%) 18 (12%)
Stage of LC at diagnosisc, d
I, n (%) 21 (32%) 28 (17%)
II, n (%) 3 (5%) 10 (6%)
IIIA, n (%) 9 (14%) 21 (13%) 0.078
IIIB-IV and extensive SCLC, n (%) 32 (49%) 104 (64%)
Follow-up months, median (range)e 95 (49-161) 104 (55-151) 0.962
LC: lung cancer; IQR: interquartile range; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer
aNot available: 5 patients
bNot available: 23 patients
cNot available in 2 Participants
dNot available in 15 Nonparticipants
eCalculated in survivors at end of study
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radiograph and were arbitrarily attributed the 6 mm
estimated visibility threshold dimension. The median
VDT of all non-baseline screen detected cases was 80
days (range: 44-318); only one of these cancers had
VDT > 300 days.
Patients with screen-detected and nonscreen-detected
LC were similar for age, gender distribution and pack-
years, as shown in Table 4. Of the screen-detected can-
cers, 32% were adenocarcinomas, none was bronchio-
loalveolar carcinoma; 47% were squamous cell
carcinomas. Among nonscreen-detected cancers the
proportion of small cell LCs was twice as high as in
screen-detected (24% vs. 12%), and the LC stage distri-
bution was significantly different from that of screen-
detected cancers (P < 0.0001). Table 5 shows the stage
distribution of screen-detected LCs. Stage I cancers
were 53% (46% at baseline; 57% at annual tests). The LC
resection rate was significantly higher in screen-detected
relative to nonscreen-detected cases (76% vs. 18%; P <
0.0001), and in participants relative to nonparticipants
(48% vs. 27%; P = 0.002). Interestingly, the LC resection
rate was essentially identical in nonparticipants and in
the control group (27% vs. 26%; P = 0.887). Among the
26 resected screen-detected LC patients there were no
hospital deaths. Follow-up of LC cases was 100% com-
plete both in the cohort and in the control group; med-
ian follow-up was 101 months (range, 49-161) and 123
months (119-131), respectively (Table 2).
Table 4 Characteristics of participants with screen-detected lung cancer (LC) and with nonscreen-detected LC
Participants with LC
Screen-detected
(n = 34)
Nonscreen-detected
(n = 33)
P
Age, median (IQR) 66 (60-71) 69 (59-72) 0.965
Male/female (ratio) 30/4 (7.5) 30/3 (10) 0.721
Pack-years, median (IQR) 55 (39-77)a 46 (33-76)b 0.200
Histologically confirmed LC, n (%) 34 (100%) 29 (88%) 0.036
Adenocarcinoma, n (%) 11 (32%) 6 (21%)
Squamous cell carcinoma, n (%) 16 (47%) 12 (41%) 0.618
Other NSCLC, n (%) 3 (9%) 4 (14%)
SCLC, n (%) 4 (12%) 7 (24%)
Stage of LC at diagnosisc
I, n (%) 18 (53%) 3 (9%)
II, n (%) 2 (6%) 1 (3%)
IIIA, n (%) 5 (15%) 4 (12%) < 0.0001
IIIB-IV and extensive SCLC, n (%) 7 (21%) 25 (76%)
Indeterminate, n (%)* 2 (6%) 0
Follow-up months, median (range)d 100 (49-161) 72 and 98e -
LC: lung cancer; IQR: interquartile range; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer
aNot available: 2 patients
bNot available: 3 patients
cNot available in 1 Nonscreen-detected Participant
*Patient refused to ascertain stage
dCalculated in survivors at end of study
eOnly two survivors
Table 5 Stage distribution of screen-detected lung cancers (LCs)
LC Stage at Diagnosis Baseline Screening
(LCs, n = 13)
Annual Screening After Baseline
(LCs, n = 21)
All Screens
(LCs, n = 34)
I, n (%) 6 (46) 12 (57) 18 (53)
II, n (%) 1 (8) 1 (5) 2 (6)
IIIA, n (%) 2 (15) 3 (14) 5 (15)
IIIB-IV, n (%) 3 (23) 4 (19) 7 (21)
Indeterminate, n (%)* 1 (8) 1 (5) 2 (6)
LC: lung cancer
*2 patients refused to complete staging procedures
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LC specific survival
Kaplan-Meier survival analysis showed significantly
greater LC survival in screen-detected cases than in
nonscreen-detected (log-rank, P < 0.0001; Figure 1A), in
participants than in nonparticipants (log-rank, P =
0.005; Figure 1B), and in the whole cohort than in the
control group (log-rank, P = 0.001; Figure 1C). Median
LC specific survival was 14.1 months (95% confidence
interval (CI), 10.9-17.2) in the whole cohort and 8.4
months (95%CI, 6.6-10.2; P = 0.001) in the controls.
The LC survival curve of the cohort and of the control
group plateaued after five years, showing persistently
higher survival in the cohort than in the control group,
until 10-year follow-up (Figure 1C). Moreover, compar-
ing controls versus nonparticipants (neither group was
screened) we found that after 5 years from diagnosis the
LC survival in these two groups was essentially identical
(Figure 1D and Table 6). All 10-year survivors had
undergone cancer resection. The 2-year, 5-year and 10-
year LC-specific survivals in all groups are shown in
Table 6. In unadjusted Cox regression, the risk of death
was lower in screen-detected LC patients relative to
nonscreen-detected (P < 0.0001), in participants relative
to nonparticipants (P = 0.013), in the whole cohort rela-
tive to the control group (hazard ratio (HR) = 0.69; 95%
CI, 0.55-0.87; P = 0.002) (Table 7). After adjusting for
gender, age, pack-years and histology, with Cox multi-
variate analysis the risk of death in the whole cohort
remained substantially unchanged (HR = 0.70; 95%CI,
0.56-0.87; P = 0.001) (Figure 2). In the cohort, 11 sub-
jects were 10-year survivors: 6 of 178 nonparticipants
(3.4%), 5 of 34 screen-detected participants (14.7%) and
none of nonscreen-detected participants. The 10-year
survivors in the control group were 4.5%.
Discussion
The impact of LC screening on a population level has
been scarcely investigated. The generally low participa-
tion rate in LC screenings (11-35%) [17,25,26] and the
volunteer effect bias [17,27] raise concern about the
generalizability to the population of interest at commu-
nity level of the results of randomized LC screening
trials of highly selected volunteers. As an example, the
recently completed National Lung Screening Trial,
(NLST) showed 20.3% mortality reduction after CT
screening in selected volunteers; however only about 7%
of smokers in the United States would meet the NLST
criteria [28]. Here we analyze the LC detection results
and the LC survival rates at community level, in the set-
ting of CXR screening offered to a clearly defined popu-
lation-based cohort of smokers. Only 21% of this cohort
participated in screening, a low attendance rate similar
to that observed in mass screening for LC in Japan
[29,30]. Analyzing the demographic features and risk
factors of the whole screening-invited cohort, we pre-
viously reported that participation was possibly
prompted by increased awareness of LC risk, while it
was not related to educational level [17].
Overall, the LC yield of our CXR screening (0.61%)
was similar to that recorded in the PLCO study (0.7%)
[31] and in the Lung Screening Study (0.68%) [32]; the
slightly lower LC yield in our screening was likely due
to lower pack-years and lower compliance. In partici-
pants, we found that only about half (51%) of LCs were
screen-detected, a proportion similar to that recorded in
the PLCO trial (53%) [31]. In the other half of partici-
pants, LCs were symptom-detected and survival was
very poor. Overall in screening participants the rates of
stage I LC diagnosis, LC resection and 5-year survival
were nearly twice as high as in nonparticipants, confirm-
ing the significantly increased resectability and survival
achievable with CXR screening [7]. Notably, the Kaplan-
Meier 10-year LC survival in the whole cohort was sig-
nificantly greater than in the control group, and by mul-
tivariate Cox analysis this survival difference was
independently related to CXR screening exposure, also
after adjusting for age, gender, pack-years and histology.
Improved LC survival persisting over 10 years in the
population-based cohort of this study suggests mortality
reduction, however no conclusion can be drawn about
the effectiveness of CXR screening, because survival may
be biased by lead-time, selection, length-time and
overdiagnosis.
We addressed the potential impact of these biases. In
the context of our study the impact of lead-time bias on
long-term LC specific survival of participants seems
negligible, because the LC specific survival curve of
screening participants plateaued after 5 years (Figure
1B). Enrolment of asymptomatic individuals in the
cohort was a source of healthy selection. The latter
however did not influence the long-term LC survival, as
shown by comparison of the Kaplan-Meier LC survival
curve of cohort’s nonparticipants and of control group
(Figure 1D); the LC survival was initially greater in non-
participants, likely due to healthy selection, but after 5
years from diagnosis it was virtually identical to that of
control group (Figure 1D and Table 6). The latter find-
ing is also consistent with the similar LC resection rate
(27% vs. 26%) and similar proportion of histological
diagnoses and of LC stage distribution in the nonpartici-
pants and in the control group (Table 2 and Table 3).
To evaluate length-time bias and overdiagnosis bias in
our study, we focused on the VDT of screen-detected
LCs, that is also an indicator of tumor aggressiveness
[33-35]. Incidence screen-detected LCs had short med-
ian VDT (80 days), and only one of these cancers had
VDT > 300 days, indicating that most of them grew
rapidly and unlikely were overdiagnosed, in agreement
Dominioni et al. BMC Cancer 2012, 12:18
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Figure 1 Comparison of lung cancer (LC) -specific survival curves (Kaplan-Meier). Shown are (A) screen-detected LCs (n = 34) vs.
nonscreen-detected LCs (n = 33), (B) screening participant LCs (n = 67) vs. nonparticipant LCs (n = 178), (C) cohort LCs (n = 245) vs. control
group LCs (n = 156), and (D) nonparticipant LCs (n = 178) vs. control group LCs (n = 156).
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Table 6 Lung cancer (LC)-specific Kaplan-Meier survival rates at 2, 5 and 10 years from LC diagnosis
LC Specific Survival
LC Patient Group 2-year Survival (%) 5-year Survival (%) 10-year Survival (%)
Screen-detected (n = 34) 70.2 48.6 48.6
Nonscreen-detected (n = 33) 12.1 12.1 —
Participants (n = 67) 41.2 30.5 30.5
Nonparticipants (n = 178) 31.6 13.5 7.6
Cohort (n = 245) 34.3 18.0 13.3
Control Group (n = 156) 21.5 13.0 8.7
LC: lung cancer
Table 7 Univariate survival analysis of clinico-pathological factors (unadjusted Cox proportional hazard model)
A B C
n = 67 n = 245 n = 401
HR HR HR
(95% CI) (95% CI) (95% CI)
Gender
Female 1.00 1.00 1.00
(reference) (reference) (reference)
Male 1.42 0.85 0.91
(0.51-3.97) (0.54-1.34) (0.63-1.32)
Age at diagn. (+1 y) 1.01 1.01 1.01
(0.97-1.06) (0.99-1.03) (0.99-1.03)
Pack/years (+1) 1.00 1.00 1.00
(0.99-1.01) (0.99-1.01) (1.00-1.01)
Histology
Adenocarcinoma 1.00 1.00 1.00
(reference) (reference) (reference)
Squamous cell ca 1.37 0.97 1.19
(0.61-3.08) (0.67-1.39) (0.9-1.58)
Other NSCLC 2.21 1.85 * 1.90 *
(0.74-6.62) (1.15-2.97) (1.29-2.79)
SCLC 2.45 * 1.79 * 1.69 *
(1.00-6.1) (1.12-2.86) (1.17-2.46)
CDO 5.60 * 2.22 * 2.44 *
(1.7-18.46) (1.44-3.45) (1.73-3.42)
Stage
I 1.00 1.00 1.00
(reference) (reference) (reference)
II 1.56 2.32 * 3.31 *
(0.19-12.98) (1.07-5.05) (1.85-5.92)
IIIA 5.94 * 4.22 * 4.08 *
(1.93-18.26) (2.37-7.53) (2.56-6.51)
IIIB - IV 14.02 * 8.38 * 8.35 *
(5.58-35.24) (5.2-13.51) (5.65-12.33)
Indeterminate 5.21 2.54 * 2.79 *
(0.61-44.11) (1.29-5.02) (1.51-5.13)
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with the observations of other authors about CXR
screen-detected LCs [22]. Moreover, among screen-
detected cancers we found no cases of bronchioloalveo-
lar carcinoma, a slow-growing subtype that may be
overdiagnosed. Furthermore, we previously showed that
the LC incidence standardized rate ratio in the whole
cohort was 1.07 [17], suggesting that the number of pos-
sibly overdiagnosed LCs was minimal.
This study has limitations. The long duration of partici-
pants’ enrolment may slightly underestimate the nonparti-
cipants’ survival [17]. Compliance with annual screening
progressively decreased, more markedly than in other
CXR screening trials. By year 3 we recorded 59% adher-
ence, while 79% was observed in the PLCO radiography
screening [16] and about 80% in the Mayo Lung Project
[36]. In our study the median number of CXR screenings
done by each participant was four, instead of five expected.
Sub-optimal compliance along with low participation rate
possibly compromised the effectiveness of screening, an
issue that will be addressed in a separate paper. Another
limitation is that the investigators assigning the cause of
death in the cohort and in the control LC group were not
blinded to mode of LC detection. Sensitivity of LC death
certificates however was shown to be high and similar in
screening participants and nonparticipants [17]; therefore,
selective misclassification of the cause of death unlikely
occurred. A relevant question is whether the 156 patients
of the control LC group are an appropriate control for the
LC patients found in the cohort. The control LC group
source were all smokers resident in the Varese district
who were diagnosed with LC during the calendar year
2000 and who met the screening criteria as of July 1997;
therefore comparison with the cohort, enrolled in 1997
and representing well the Varese smokers population [17]
appears meaningful. We ruled out the possibility of per-
iod-effect for the year 2000 LC survival, because differ-
ences of LC survival in the cohort by pair-wise years of
cancer diagnosis (1997-1998, 1999-2000, 2001-2002, 2003-
2004, 2005-2006) were not significant (log-rank, P =
0.401). Indeed the control group LCs closely represented
the cohort LCs as for age, gender, pack-years, proportion
of histologically confirmed LCs, distribution of LC types
and stages, and duration of follow-up (Table 2). Moreover,
for the evaluation of long-term survival of the cohort, the
control group seems appropriate because the cohort’s
nonparticipants and the controls (neither group was
screened) had similar long-term survival (Table 6).
Another limitation is the small number of screen-detected
LC cases; their survival rates therefore must be interpreted
with caution. Strong features of this study are the comple-
teness of the list of all eligible smokers resident in the 50
widely scattered communities invited to screening, and the
completeness of follow-up of all LCs of the cohort and of
the control group.
Table 7 Univariate survival analysis of clinico-pathological factors (unadjusted Cox proportional hazard model)
(Continued)
Unexposed 33 LCs 1.00 178 LCs 1.00 156 LCs 1.00
(reference) (reference) (reference)
Exposed 34 LCs 0.26 ** 67 LCs 0.62 *** 245 LCs 0.69 ****
(0.14-0.49) (0.44-0.86) (0.55-0.87)
Shown are (A) 67 lung cancers (LCs) of screening participants, (B) 245 LCs of the cohort, and (C) 401 LCs (156 of control group and 245 of cohort)
HR: hazard ratio; CI: confidence interval; NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; CDO: clinical diagnosis only; LC: lung cancer
*P < 0.0001
**P < 0.0001 (34 LCs Screen-detected vs. 33 LCs Nonscreen-detected)
***P = 0.0013 (67 LCs of Participants vs. 178 LCs of Nonparticipants)
****P = 0.002 (245 LCs of Cohort vs. 156 LCs of Control Group)
Figure 2 Multivariate analysis (Cox-proportional hazard model)
of the impact of lung cancer (LC) screening on survival. Shown
are (A) analysis of 67 LCs of participants (screen- vs. nonscreen-
detected), (B) analysis of 245 LCs of the cohort (participants vs.
nonparticipants), and (C) analysis of 401 LCs (156 LCs of control
group vs. 245 LCs of the cohort). All the models were adjusted for
gender, age, pack-years and histology.
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Conclusion
This report documents increased 10-year LC-specific
survival in an entire population-based cohort of 5,815
smokers invited to CXR screening at community level.
This favourable long-term effect was obtained in spite of
low (21%) screening participation rate and was indepen-
dently related to CXR screening exposure. Whether
enhanced LC-specific survival in the cohort corresponds
to mortality reduction remains to be evaluated.
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